DURECT (NASDAQ:DRRX) appointed Timothy Papp as chief financial officer to direct and oversee all financial and capital markets activities, including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations.
“We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT,” James Brown, D.V.M., president and CEO of DURECT, said in a statement.
Mr. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector. He joins DURECT from RBC Capital Markets, where he was a managing director of healthcare investment banking. Previously, he served as a managing director of healthcare investment banking at Stifel, and he also served in investment banking and mergers & acquisitions roles at Cowen, Keybanc Capital Markets, and Rodman & Renshaw.
Mr. Papp said he believes that larsucosterol is an “underappreciated asset that has the potential to transform the treatment of alcohol-associated hepatitis as well as other indications.”
